Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

<b>:</b><b> </b>Immunotherapy based on anti PD-1/PD-L1 inhibitors has proven to be more effective than sunitinib in the first-line setting of advanced renal cell carcinoma (RCC). RCC patients with sarcomatoid histology (sRCC) have a poor prognosis and limited therapeutic opti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Carlo Buonerba, Pasquale Dolce, Simona Iaccarino, Luca Scafuri, Antonio Verde, Ferdinando Costabile, Martina Pagliuca, Rocco Morra, Vittorio Riccio, Dario Ribera, Pietro De Placido, Valeria Romeo, Felice Crocetto, Nicola Longo, Ciro Imbimbo, Sabino De Placido, Giuseppe Di Lorenzo
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI AG 2020-02-01
Schriftenreihe:Cancers
Schlagworte:
renal cell carcinoma
sarcomatoid
immune checkpoint inhibitors
pd-1
pd-l1
Online Zugang:https://www.mdpi.com/2072-6694/12/2/408
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge